Focus: Pliant Therapeutics is a mid-cap biotechnology company focused on developing treatments for fibrotic diseases, with a pipeline spanning respiratory, oncology, and cholestatic liver disease indications.
Profile data last refreshed 11h ago · AI intelligence enriched 2mo ago
Best for mission-driven scientists seeking fibrosis-focused discovery and early-stage development work at a financially solvent but operationally lean biotech.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Pliant Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Pliant Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
David Raben receives a 575,000-share option at $1.05 per share from Pliant Therapeutics (PLRX). - Stock Titan
David Raben receives a 575,000-share option at $1.05 per share from Pliant Therapeutics (PLRX). Stock Titan
[Form 3] PLIANT THERAPEUTICS, INC. Initial Statement of Beneficial Ownership - Stock Titan
[Form 3] PLIANT THERAPEUTICS, INC. Initial Statement of Beneficial Ownership Stock Titan
Pliant Therapeutics Names David Raben CMO - Voice of Healthcare
Pliant Therapeutics Names David Raben CMO Voice of Healthcare
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer - Investing News Network
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer Investing News Network
Pliant Therapeutics Receives FDA Fast Track Designation for - GlobeNewswire
Pliant Therapeutics Receives FDA Fast Track Designation for GlobeNewswire
Pliant Therapeutics (PLRX) gains 8.9% institutional holder in ADAR1 Capital - Stock Titan
Pliant Therapeutics (PLRX) gains 8.9% institutional holder in ADAR1 Capital Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: state DOL filings, aggregated via Big Local News
Recent layoff amid improving financial metrics suggests operational restructuring; risk of further headcount adjustments if Phase 2 data disappoints.
Recent peer-reviewed publications with author affiliations at this company
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial.
Artificial intelligence, machine learning-based automated fibrosis quantification in preclinical models of pulmonary fibrosis.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo